<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 1)*
Under the Securities Exchange Act of 1934
BIOGEN,INC.
-----------
(Name of Issuer)
COMMON STOCK
------------
(Title of Class of Securities)
090597105
---------
(CUSIP Number)
Copy to:
Daniel Schlatter Daniel L. Goelzer, Esq.
Theaterstrasse 12, Baker & McKenzie
8024 Zurich, CH/Switzerland 815 Connecticut Ave., N.W.
41-1-267-67-67 Washington, D.C. 20006
-----------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
July 6, 1994
------------
(Date of Event which Requires
Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box / /.
Check the following box if a fee is being paid with the statement / /.
(A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent of
the class of securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent or less of
such class.) (See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom copies
are to be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
Page 1 of 10 Pages
<PAGE> 2
CUSIP No. 090597105
- -------------------
- --------------------------------------------------------------------------------
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
BB Biotech AG
- --------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /x/
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source of Funds (See Instructions)
WC
- --------------------------------------------------------------------------------
(5) Check Box if Disclosure of Legal Proceedings / /
is Required Pursuant to Item 2(d) or 2(e)
- --------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
Switzerland
- --------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power:
Beneficially Owned 0
by Each Reporting ----------------------------------------
Person With (8) Shared Voting Power
2,840,000
----------------------------------------
(9) Sole Dispositive Power
0
----------------------------------------
(10) Shared Dispositive Power
2,840,000
----------------------------------------
- --------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
2,840,000 shares
- --------------------------------------------------------------------------------
(12) Check Box if the Aggregate Amount in Row (11) / /
Excludes Certain Shares (See Instructions)
- --------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
8.25%
- --------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions)
HC, CO
- --------------------------------------------------------------------------------
Page 2 of 10 Pages
<PAGE> 3
CUSIP No. 090597105
- -------------------
- --------------------------------------------------------------------------------
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Biotech Invest S.A.
- --------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /x/
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source of Funds (See Instructions)
WC
- --------------------------------------------------------------------------------
(5) Check Box if Disclosure of Legal Proceedings / /
is Required Pursuant to Item 2(d) or 2(e)
- --------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
Panama
- --------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 1,080,000
by Each Reporting --------------------------------
Person With (8) Shared Voting Power
0
--------------------------------
(9) Sole Dispositive Power
1,080,000
--------------------------------
(10) Shared Dispositive Power
0
--------------------------------
- --------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Pers
1,080,000 Shares
- --------------------------------------------------------------------------------
(12) Check Box if the Aggregate Amount in Row (11) / /
Excludes Certain Shares (See Instruction)
- --------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
3.14%
- --------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions)
CO
- --------------------------------------------------------------------------------
Page 3 of 10 Pages
<PAGE> 4
CUSIP No. 090597105
- -------------------
- --------------------------------------------------------------------------------
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Biotech Focus S.A.
- --------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /x/
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source of Funds (See Instructions)
WC
- --------------------------------------------------------------------------------
(5) Check Box if Disclosure of Legal Proceedings / /
is Required Pursuant to Item 2(d) or 2(e)
- --------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
Panama
- --------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 800,000
by Each Reporting --------------------------------
Person With (8) Shared Voting Power
0
--------------------------------
(9) Sole Dispositive Power
800,000
--------------------------------
(10) Shared Dispositive Power
0
--------------------------------
- --------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
800,000 shares
- --------------------------------------------------------------------------------
(12) Check Box if the Aggregate Amount in Row (11) / /
Excludes Certain Shares (See Instructions)
- --------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
2.32%
- --------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions)
CO
- --------------------------------------------------------------------------------
Page 4 of 10 Pages
<PAGE> 5
CUSIP No. 090597105
- -------------------
- --------------------------------------------------------------------------------
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Biotech Target S.A.
- --------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /x/
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source of Funds (See Instructions)
WC
- --------------------------------------------------------------------------------
(5) Check Box if Disclosure of Legal Proceedings / /
is Required Pursuant to Item 2(d) or 2(e)
- --------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
Panama
- --------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 960,000
by Each Reporting --------------------------------
Person With (8) Shared Voting Power
0
--------------------------------
(9) Sole Dispositive Power
960,000
--------------------------------
(10) Shared Dispositive Power
0
--------------------------------
- --------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
960,000 shares
- --------------------------------------------------------------------------------
(12) Check Box if the Aggregate Amount in Row (11) / /
Excludes Certain Shares (See Instructions)
- --------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
2.79%
- --------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions)
CO
- --------------------------------------------------------------------------------
Page 5 of 10 Pages
<PAGE> 6
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
ITEM 3 IS HEREBY AMENDED TO ADD THE FOLLOWING:
From May 24, 1994 to August 2, 1994, the Biotech Subsidiaries
have purchased an additional 690 shares of Biogen Common Stock, for an
aggregate consideration in excess of US$20 million. Each of the Biotech
Subsidiaries used working capital to purchase the shares of Biogen Common
Stock, which, in turn, was supplied by BB Biotech.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
ITEMS 5(a) AND 5(b) ARE AMENDED IN THEIR ENTIRETY TO READ AS FOLLOWS:
(a) BB Biotech may be deemed to be the indirect beneficial owner
of the 2,840,000 shares of Biogen Common Stock held directly in the aggregate
by the Biotech Subsidiaries as of August 2, 1994, which represents 8.25% of the
outstanding shares of Biogen Common Stock. No shares of Biogen Common Stock
are directly owned by BB Biotech. As of August 2, 1994, Biotech Invest
beneficially owned 1,080,000 shares of Biogen Common Stock, representing 3.14%
of the outstanding shares of Biogen Common Stock. As of August 2, 1994,
Biotech Focus beneficially owned 800,000 shares of Biogen Common Stock,
representing 2.32% of the outstanding shares of Biogen Common Stock. As of
August 2, 1994, Biotech Target beneficially owned 960,000 shares of Biogen
Common Stock, representing 2.79% of the outstanding shares of Biogen Common
Stock. To the best knowledge of BB Biotech and the Biotech Subsidiaries, no
director or executive officer of BB Biotech or the Biotech Subsidiaries owns
any shares of Biogen Common Stock.
(b) The number of shares of Biogen Common Stock to which there is
sole power to vote or to direct the vote, shares power to vote or to direct the
vote, sole power to dispose or to direct the disposition, or shared power to
dispose or direct the disposition is set forth in the cover pages and such
information is incorporated herein by reference. BB Biotech, through its
ownership of the Biotech Subsidiaries, may be deemed to beneficially own the
shares of Biogen Common Stock within the meaning of Regulation 13D under the
Exchange Act, and may be deemed to share with the Biotech Subsidiaries the
power to vote or direct the vote of and the power to dispose of or direct the
disposition of the aggregate 2,840,000 shares of Biogen Common Stock held by
the Biotech Subsidiaries. BB Biotech hereby expressly declares that the filing
of this statement shall not be construed as an admission that it is, for
purposes of Section 13(d) of the Exchange Act, the beneficial owner of the
shares of Biogen Common Stock held by the Biotech Subsidiaries.
ITEM 5(c) IS HEREBY AMENDED TO ADD THE FOLLOWING:
(c) An additional summary of transactions in Biogen Common Stock
effected by the Biotech Subsidiaries is attached hereto as Exhibit A.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
ITEM 7 IS HEREBY AMENDED TO ADD THE FOLLOWING:
Exhibit 99.G: Agreement by and among BB Biotech, Biotech Invest, Biotech
Focus, and Biotech Target with respect to the filing of this
Amendment No. 1 to a statement on Schedule 13D dated June 2,
1994.
Page 6 of 10 Pages
<PAGE> 7
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
BB BIOTECH AG
Date: August 9, 1994 By: /s/ DANIEL SCHLATTER
-----------------------------
Name: Daniel Schlatter
Title: Counsel
By: /s/ DR. ERNST MUELLER-MOEHL
-----------------------------
Name: Dr. Ernst Mueller-Moehl
BIOTECH INVEST, S.A.
Date: August 9, 1994 By: /s/ DANIEL SCHLATTER
-----------------------------
Name: Daniel Schlatter
Title: Counsel
BIOTECH FOCUS, S.A.
Date: August 9, 1994 By: /s/ DANIEL SCHLATTER
-----------------------------
Name: Daniel Schlatter
Title: Counsel
BIOTECH TARGET, S.A.
Date: August 9, 1994 By: /s/ DANIEL SCHLATTER
-----------------------------
Name: Daniel Schlatter
Title: Counsel
Page 7 of 10 Pages
<PAGE> 8
EXHIBIT INDEX
Exhibit 99.A Amended Transaction Summary
Exhibit 99.G Joint Filing Agreement
<PAGE> 1
Exhibit A
EXHIBIT A IS HEREBY AMENDED TO ADD THE FOLLOWING SUMMARY OF
TRANSACTIONS IN BIOGEN COMMON STOCK EFFECTED BY THE BIOTECH SUBSIDIARIES FROM
MAY 24, 1994 TO AUGUST 2, 1994.
<TABLE>
<CAPTION>
PERCENT
TYPE OF TRANSACTION, NUMBER, CLASS AND PRICE OF BENEFICIALLY TOTAL SHARES OF OUTSTANDING
DATE SHARES OWNED SHARES OUTSTANDING OWNED
---- ----------------------------------------------- ------------ ------------ --------------
<S> <C> <C> <C> <C>
May 24, 1994 Purchase by Biotech 2,240,000 34,430,000 6.51%
Target of 90,000 shares of shares of Common
Common Stock at an average price per share of Stock
$30.00.
June 20, 1994 Purchase by Biotech 2,300,000 34,430,000 6.68%
Target of 60,000 shares of shares of Common
Common Stock at an average price per share of Stock
$29.00.
June 22, 1994 Purchase by Biotech 2,460,000 34,430,000 7.15%
Target of 160,000 shares of shares of Common
Common Stock at an average price per share of Stock
$27.92.
June 30, 1994 Purchase by Biotech 2,530,000 34,430,000 7.35%
Target of 70,000 shares of shares of Common
Common Stock at an average price per share of Stock
$29.75.
June 30, 1994 Purchase by Biotech 2,540,000 34,430,000 7.38%
Target of 10,000 shares of shares of Common
Common Stock at an average price per share of Stock
$28.50.
July 6, 1994 Purchase by Biotech 2,640,000 34,430,000 7.67%
Invest of 100,000 shares of shares of Common
Common Stock at an average price per share of Stock
$29.00.
July 7, 1994 Purchase by Biotech 2,740,000 34,430,000 7.96%
Target of 100,000 shares of shares of Common
Common Stock at an average price per share of Stock
$29.13.
</TABLE>
Page 8 of 10 Pages
<PAGE> 2
<TABLE>
<CAPTION>
PERCENT
TYPE OF TRANSACTION, NUMBER, CLASS AND PRICE OF BENEFICIALLY TOTAL SHARES OF OUTSTANDING
DATE SHARES OWNED SHARES OUTSTANDING OWNED
---- ----------------------------------------------- ------------ ------------ --------------
<S> <C> <C> <C> <C>
August 2, 1994 Purchase by Biotech 2,840,000 34,430,000 8.25%
Target of 100,000 shares of shares of Common
Common Stock at an average price per share of Stock
$41.66.
</TABLE>
Page 9 of 10 Pages
<PAGE> 1
Exhibit G
JOINT FILING AGREEMENT
We, the undersigned, hereby express our agreement that the
attached Amendment No. 1 to a statement on Schedule 13D dated June 2,
1994, is filed on behalf of each of the undersigned.
Date: August 9, 1994
BB BIOTECH AG
By: /s/ Daniel Schlatter
-----------------------------
Name: Daniel Schlatter
Title: Counsel
By: /s/ Dr. Ernst Mueller-Moehl
-----------------------------
Name: Dr. Ernst Mueller-Moehl
BIOTECH INVEST, S.A.
By: /s/ Daniel Schlatter
-----------------------------
Name: Daniel Schlatter
Title: Counsel
BIOTECH FOCUS, S.A.
By: /s/ Daniel Schlatter
-----------------------------
Name: Daniel Schlatter
Title: Counsel
BIOTECH TARGET, S.A.
By: /s/ Daniel Schlatter
-----------------------------
Name: Daniel Schlatter
Title: Counsel
Page 10 of 10 Pages
